Horizon Therapeutics Public Limited Company
Officers & Directors
1. Timothy P. Walbert (Chairman, President and Chief Executive Officer): Timothy Walbert has been the CEO of Horizon Therapeutics since 2008, leading the company in its mission of developing innovative medicines for rare and rheumatic diseases. Prior to joining Horizon, Walbert held executive leadership roles at several pharmaceutical companies, including G.D. Searle, Heska Corporation and NeoPharm.
2. Paul Hoelscher (Executive Vice President and Chief Financial Officer): Paul Hoelscher joined Horizon in 2017, bringing more than 20 years of finance and operations experience to the company. Prior to joining Horizon, he served in various financial leadership positions at Allergan, including as Senior Vice President of Finance for Global Operations and Corporate Financial Planning and Analysis.
3. Shao-Lee Lin (Executive Vice President and Chief Scientific Officer): Dr. Shao-Lee Lin has been with Horizon since the company's inception in 2006, leading the company's research and development efforts. She has over 20 years of experience in drug discovery and development, including roles at Abbott Laboratories and Tularik Inc.
4. Geoffrey M. Curtis (Executive Vice President and Chief Commercial Officer): With over 30 years of experience in the pharmaceutical industry, Geoffrey Curtis leads Horizon's global commercial strategy and execution. Prior to joining Horizon, he held senior commercial roles at Baxter Healthcare, Hospira and Novartis.
5. John C. Kody (Executive Vice President, General Counsel and Secretary): John Kody has been with Horizon since 2011, overseeing the company's legal and regulatory affairs. Prior to Horizon, he served as General Counsel for NeoPharm and held various legal roles at Abbott Laboratories.
DIRECTORS:
1. Timothy P. Walbert: See above.
2. William J. Kelly: William Kelly has been a member of Horizon's Board of Directors since 2015. He is also currently the Chairman of the Board for Allscripts Healthcare Solutions and previously served as the President and CEO of Healthcare Financial Management Association.
3. George A. Scangos: Dr. George Scangos has been a member of Horizon's board since 2015. He is also currently the CEO of Vir Biotechnology and previously served as the CEO of Biogen.
4. Michele L. Griffin: Michele Griffin has been a member of Horizon's board since 2017. She is also currently an Executive in Residence at Frazier Healthcare Partners and previously served as the CEO of Invitae Corporation and the President of GSK Consumer Healthcare North America.
5. Robert J. De Vaere: Robert De Vaere has been a member of Horizon's board since 2015. He is also currently a Managing Partner at Deerfield Management and previously held leadership roles at Zaffre Investments, Millennium Pharmaceuticals and McKinsey & Company.
Horizon Therapeutics Public Limited Company currently has 1300 employees.
|
